Format

Send to

Choose Destination
Leukemia. 2019 May 21. doi: 10.1038/s41375-019-0476-y. [Epub ahead of print]

Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.

Author information

1
Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
2
Department of Medicine, Weill Cornell Medical College, New York, NY, 10021, USA.
3
Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
4
Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
5
Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. peralesm@MSKCC.ORG.
6
Department of Medicine, Weill Cornell Medical College, New York, NY, 10021, USA. peralesm@MSKCC.ORG.
PMID:
31114023
DOI:
10.1038/s41375-019-0476-y

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center